Conference Correspondent

Conference Correspondent

Novel triplet combinations are being evaluated in both the newly diagnosed and relapsed/refractory settings in multiple myeloma. This study evaluates the efficacy and safety of ixazomib, pomalidomide, and dexamethasone combination therapy in a heavily pretreated, high-risk patient population.

Payers seek to understand the value of myeloma treatment options by assessing outcomes relative to cost. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.

As more patients receive maintenance therapy for multiple myeloma, researchers seek to evaluate the impact of toxicities associated with long-term treatment on health-related quality of life in these patient populations.

Recent data showed that lenalidomide maintenance therapy is an effective option for both transplant-eligible and nontransplant-eligible patients with multiple myeloma.

The majority of patients with smoldering multiple myeloma do not receive active treatment. In this study, treatment of a high-risk population with lenalidomide and dexamethasone yielded favorable patient outcomes.

Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.

Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.

This phase 2 study of elotuzumab, lenalidomide, and dexamethasone combination therapy in a high-risk population of patients with smoldering multiple myeloma showed promising efficacy and tolerability.

New treatment approaches are needed in multiple myeloma to extend relapse-free intervals and overall survival. In a phase 1/2 trial, the combination of pomalidomide, dexamethasone, and weekly carfilzomib showed impressive efficacy with acceptable tolerability.

In this analysis, Connect MM, a large observational disease registry, was used to characterize evolving treatment patterns and outcomes for patients with newly diagnosed multiple myeloma.

Page 9 of 12
Results 81 - 90 of 111
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME